Talphera, Inc. (TLPH) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Talphera, Inc. is a specialty pharmaceutical company focused on developing therapies for medically supervised settings. The company recently changed its name from AcelRx Pharmaceuticals, Inc. in January 2024. Its primary development focus is Niyad (a regional anticoagulant for dialysis circuits) and LTX-608 (nafamostat for IV infusion). The company divested its commercial product, DSUVIA, to Alora Pharmaceuticals in April 2023, retaining rights to certain future payments.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | YTD 9M 2024 | YTD 9M 2023 |
|---|---|---|---|---|
| Revenue | $0 | $0.1M | $0 | $0.4M |
| Net Loss | $(3.4M) | $(1.4M) | $(11.1M) | $(13.9M) |
| Loss Per Share (Basic/Diluted) | $(0.13) | $(0.08) | $(0.43) | $(1.08) |
| Cash & Equivalents | $11.1M | $13.4M | $11.1M | $13.4M |
| Total Assets | $21.0M | $20.4M | $21.0M | $20.4M |
| Total Liabilities | $11.4M | $6.3M | $11.4M | $6.3M |
| Stockholders' Equity | $9.6M | $14.1M | $9.6M | $14.1M |
Note: Revenue is zero as the company has no commercial products currently generating sales; prior year revenue was related to the divested DSUVIA business.
Material Changes vs. Prior Period
- Operating Expenses: Research and Development (R&D) expenses increased by 74% in Q3 2024 ($2.1M) compared to Q3 2023 ($1.2M), driven by the advancement of the Niyad clinical trial. Selling, General, and Administrative (SG&A) expenses decreased by 25% in Q3 2024 ($1.7M vs. $2.2M) due to headcount reductions and the divestiture of DSUVIA.
- Other Income: The company recognized a $1.2M gain on the sale of future payments in the first quarter of 2024 related to an agreement with XOMA. In Q3 2024, the company recorded a $0.2M gain on the change in fair value of warrant liabilities, compared to a $1.7M gain in Q3 2023.
- Liquidity: Cash and cash equivalents increased to $11.1M from $5.7M at year-end 2023, bolstered by a $6.0M private placement in January 2024 and proceeds from the sale of future payments.
- Liabilities: Total liabilities increased significantly due to the recording of a $6.5M liability related to the sale of future payments to XOMA.
Outlook, Risks, and Management Commentary
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. Current cash resources are not expected to fund operations for the next 12 months. The company plans to raise additional capital through equity offerings, debt, or strategic partnerships.
- DSUVIA Update: In October 2024, Alora Pharmaceuticals notified Talphera that it is discontinuing sales efforts for DSUVIA. The impact on future Department of Defense (DoD) sales and the associated milestone payments remains uncertain.
- Clinical Progress: The company is focused on the NEPHRO CRRT registrational trial for Niyad. A second tranche of a private placement (up to $12M) is contingent on achieving primary and secondary endpoints by September 30, 2024, or meeting specific stock price targets. This deadline was amended to June 30, 2025, for certain investors.
- Legal Proceedings: A securities class action lawsuit regarding DSUVIA marketing was dismissed with prejudice in May 2024, but plaintiffs have appealed. The company intends to vigorously defend against the appeal.
- Supply Chain: The company relies on single sources for nafamostat active pharmaceutical ingredients and finished goods, with manufacturing located outside the U.S., creating potential supply chain risks.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the next capital raise given the "substantial doubt" regarding going concern status.
- DSUVIA Revenue Impact: Assess the financial impact of Alora discontinuing DSUVIA sales efforts on future milestone payments and the XOMA agreement.
- Niyad Trial Status: Confirm the enrollment and data readout status of the NEPHRO CRRT trial, which is critical for the conditional equity tranche.
- Warrant Liability: Monitor the fair value of the warrant liability, which fluctuates with stock price and volatility, impacting net income/loss.
- Legal Appeal: Track the status of the appeal regarding the dismissed securities class action lawsuit.